Arrivent Biopharma Inc.

Company Overview

Business Model: ARRIVENT BIOPHARMA, INC. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address unmet medical needs in oncology, with an initial focus on solid tumors. The company aims to leverage its drug development expertise to advance its lead product candidate, firmonertinib, and a pipeline of novel therapeutics, including next-generation antibody drug conjugates (ADCs) such as ARR-217 (MRG007). Its strategy involves evaluating research collaborations, partnerships, and licensing arrangements to expand its development pipeline, with an initial focus on in-licensing innovative therapies from China for global development. ARRIVENT BIOPHARMA, INC. currently has no products approved for sale and has not generated any revenue from product sales.

Market Position: ARRIVENT BIOPHARMA, INC. targets significant unmet medical needs in non-small cell lung cancer (NSCLC), particularly in patients with uncommon epidermal growth factor receptor (EGFR) mutations, such as exon 20 insertion and P-loop and-alpha-c-helix compressing (PACC) mutations, which are underserved by existing treatments. Firmonertinib, the lead candidate, is designed to inhibit both classical and uncommon EGFR mutations. The company received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) in October 2023 for firmonertinib in first-line EGFRm NSCLC with exon 20 insertion, and Orphan Drug Designation in February 2024 for NSCLC with EGFRm or human epidermal growth factor receptor 2 (HER2) mutations or human epidermal growth factor receptor 4 (HER4) mutations. Firmonertinib is currently approved and commercially distributed by Shanghai Allist Pharmaceuticals, Co. Ltd (Allist) in China as a first-line therapy for classical EGFRm NSCLC. The competitive landscape includes large and specialty pharmaceutical and biotechnology companies with significantly greater financial resources and expertise.

Recent Strategic Developments:

• October 2023: Received Breakthrough Therapy Designation (BTD) from the FDA for firmonertinib for first-line EGFRm NSCLC with exon 20 insertion.
• February 2024: Received Orphan Drug Designation for firmonertinib for treatment of NSCLC with EGFRm or HER2 mutations or HER4 mutations.
• June 2021 (amended November 6, 2023): Licensed global rights (excluding greater China) to develop and commercialize firmonertinib from Allist.
• December 2021 (amended June 30, 2023, and August 9, 2024): Entered into a research collaboration with Aarvik Therapeutics, Inc. (Aarvik) to discover next-generation ADCs, and exercised an exclusive option in August 2024.
• June 2024: Entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) to discover, develop, and commercialize novel ADCs for cancers globally (excluding greater China).
• January 2025: Entered into an Exclusive License Agreement with Lepu Biopharma Co. Ltd. (Lepu Biopharma) to develop and commercialize ARR-217 (MRG007), a CD-H17-targeting ADC for gastrointestinal cancers, outside greater China.
• December 2025: Dosed the first patient in ALPACCA, a global, pivotal Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic EGFRm NSCLC patients with PACC mutations.
• July 2025: Completed an underwritten public offering, issuing 3,059,615 shares of common stock and 1,363,469 pre-funded warrants, generating net proceeds of $80.5 million.
• February 2025: Initiated an "at-the-market" offering program with Jefferies LLC, selling 5,560,266 shares of common stock for net proceeds of $122.2 million during 2025.
• May 2025: Entered into a $75 million loan and security agreement with Silicon Valley Bank, with no amounts drawn as of December 31, 2025.
• September 2025: Announced final Phase 1b data from the FURTHER trial for firmonertinib in first-line PACC mutations, reporting a 68.2% confirmed overall response rate (cORR), 16.0 months median progression-free survival (mPFS), and 14.6 months median duration of response (DOR) in the 240 mg cohort.

Geographic Footprint: ARRIVENT BIOPHARMA, INC.'s licensed territories for firmonertinib, ARR-217, and ADCs from Alphamab are worldwide, excluding greater China (mainland China, Hong Kong, Macau, and Taiwan). The company conducts global clinical trials for firmonertinib (FURVENT, FURTHER, ALPACCA) in the United States, Europe, and certain Asian countries including China. The FAVOUR trial for firmonertinib and the initial clinical study for ARR-217 are conducted by partners in China. Manufacturing relies on third-party contract manufacturers primarily located in China. All of ARRIVENT BIOPHARMA, INC.'s assets are located in the United States, where it also maintains office spaces in the San Francisco Peninsula and Washington, D.C./Maryland area.

Financial Performance

Revenue Analysis

ARRIVENT BIOPHARMA, INC. has not generated any revenue from product sales or otherwise since its inception.

Profitability Metrics:

• Gross Margin: Not applicable (no revenue)
• Operating Margin: Not applicable (no revenue)
• Net Margin: Not applicable (no revenue)

Investment in Growth:

• R&D Expenditure: $153.4 million (100% of total operating expenses)
• Strategic Investments:
  • $5.0 million in clinical milestone payments to Allist in 2025.
  • $40.0 million upfront payment to Lepu Biopharma in January 2025.
  • $1.0 million developmental milestone payment to Lepu Biopharma in Q2 2025.
  • $1.2 million payment to Alphamab upon target pair selection approval in 2025.
  • $1.0 million option exercise payment to Aarvik in August 2024.
  • $4.6 million in cost reimbursements to Alphamab in 2025 ($1.7 million expensed as R&D).
  • $0.6 million in cost reimbursements to Allist in 2025.

Business Segment Analysis

ARRIVENT BIOPHARMA, INC. operates as a single reportable segment: life science. The Chief Executive Officer, as the chief operating decision maker, assesses performance based on net loss.

Firmonertinib

Financial Performance:

• R&D Expenses: $67.6 million in 2025 (+32.9% YoY from $50.9 million in 2024).
• Key Growth Drivers: Firmonertinib is a novel, EGFR mutant-selective TKI being developed for NSCLC patients with a broader set of EGFR mutations, including uncommon exon 20 insertion and PACC mutations. It has demonstrated brain penetrance in preclinical and clinical studies. The company believes it has the potential to become a chemotherapy-free oral regimen for exon 20 insertion mutations and a leading treatment option for PACC mutations.

Product Portfolio:

• Firmonertinib: An investigational, novel, EGFR mutant-selective TKI. It is currently approved and commercially distributed by Allist in China as a first-line therapy for classical EGFRm NSCLC, for pre-treated patients with T790M mutations, and more recently for patients who have failed first-line therapy in Exon20 insertion mutations.

Market Dynamics: Lung cancer is a significant global health burden, with NSCLC accounting for approximately 85% of cases. EGFR mutations are prevalent in NSCLC, with uncommon mutations (exon 20 insertion and PACC mutations) accounting for approximately 22% of EGFRm NSCLC patients and associated with lower life expectancy. Existing third-generation EGFR TKIs (e.g., osimertinib from AstraZeneca plc) are minimally active or not approved for these uncommon mutations. Current first-line standard of care for exon 20 insertion mutations involves platinum-based chemotherapy, with or without amivantamab (Johnson & Johnson), which has limitations such as lack of brain penetrance and intravenous administration with associated toxicities. For PACC mutations, treatment guidelines are not established, often leading to chemotherapy with limited efficacy.

Sub-segment Breakdown:

• FURVENT (Phase 3, Exon 20 Insertion): $48.7 million R&D expense in 2025 (+42.8% YoY). This is a global, pivotal Phase 3 clinical trial with 398 patients, evaluating firmonertinib (160 mg or 240 mg once-daily) against platinum-based chemotherapy with pemetrexed. The primary endpoint is PFS, with topline data expected in mid-2026.
• FURTHER (Phase 1b, PACC Mutations): $9.8 million R&D expense in 2025 (-19.9% YoY). This global Phase 1b dose escalation and expansion trial includes a cohort of 60 TKI-treatment-naïve PACC EGFRm NSCLC patients. Final data (September 2025) for the 240 mg first-line cohort showed a 68.2% cORR, 16.0 months mPFS, and 14.6 months median DOR. Confirmed CNS responses were also observed.
• FAVOUR (Phase 1b, Exon 20 Insertion): $0.4 million R&D expense in 2025 (+46.0% YoY). This ongoing 90-patient Phase 1b trial, conducted by Allist in China, showed a 79% cORR and 15.2 months median DOR in treatment-naïve patients (240 mg once-daily).
• ALPACCA (Phase 3, PACC Mutations): The first patient was dosed in December 2025 in this global, pivotal Phase 3 clinical trial, which plans to enroll 480 patients. It compares firmonertinib (240 mg once-daily) to investigator’s choice of osimertinib or afatinib, with co-primary endpoints of ORR and PFS. The study design allows for potential accelerated approval based on ORR.
• Planned Adjuvant Study: The company intends to participate in or conduct a global Phase 3 clinical trial in 2026 to investigate firmonertinib as adjuvant therapy for Stage IIB to IIIB EGFRm NSCLC patients with uncommon mutations (including exon 20 insertion and PACC) after surgical resection.

Antibody Drug Conjugates (ADCs)

Financial Performance:

• R&D Expenses (Early-stage programs, includes ADCs): $55.5 million in 2025 (+407.0% YoY from $10.9 million in 2024), largely due to a $40.0 million upfront payment to Lepu Biopharma.
• Key Growth Drivers: Advancing next-generation ADCs to improve activity and safety over conventional single-target bivalent ADCs by targeting chemotherapy more directly to tumor cells.

Product Portfolio:

• ARR-217 (MRG007): A CD-H17-targeting ADC for gastrointestinal cancers, currently in Phase 1 clinical development (initial study in China). Licensed from Lepu Biopharma for ex-Greater China rights.
• ARR-002: A preclinical candidate identified through the Aarvik collaboration, with IND-enabling activities initiated. This ADC leverages Aarvik's proprietary multi-target, multivalent, site-specific conjugation antibody platform.
• ARR-421 program: An early-stage program resulting from a collaboration with Alphamab, leveraging their proprietary linker-payload platform and glycan-conjugation technology.

Market Dynamics: ADCs are a promising modality for cancer treatment, but current ADCs face limitations due to dose-limiting toxicities and heterogeneous target expression within tumors.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: ARRIVENT BIOPHARMA, INC. has never declared or paid cash dividends and intends to retain all available funds and future earnings for business development and expansion.
• Dividend Yield: 0%
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $45.5 million
• Total Debt: $0 (No amounts drawn on the $75.0 million credit facility with Silicon Valley Bank as of December 31, 2025).
• Net Cash Position: $45.5 million
• Debt Maturity Profile: A $75.0 million credit facility with Silicon Valley Bank matures on March 1, 2030 (or March 1, 2029 if certain conditions are not met).

Cash Flow Generation (Year Ended December 31, 2025):

• Operating Cash Flow: $(160.6) million (Net cash used in operating activities).

Operational Excellence

Production & Service Model: ARRIVENT BIOPHARMA, INC. relies on third-party Contract Manufacturing Organizations (CMOs) for the development and manufacture of product candidates for clinical trials and expects to continue this reliance for potential commercial supply. This strategy aims to maintain an efficient infrastructure and focus internal expertise on clinical development and commercialization.

Supply Chain Architecture: Key Suppliers & Partners:

• Drug Substance & Product Manufacturers:
  • Zhejiang Raybow Pharmaceutical Company., Ltd. (Raybow) and SynTheAll Pharmaceutical Co., Ltd. (WuXi STA) supply firmonertinib drug substance for clinical trials.
  • WuXi STA manufactures firmonertinib drug product for clinical trials and initial commercial launch supplies.
  • Manufacturers in China are expected to supply ARR-217 drug substance and product for clinical studies.
  • WuXi XDC Cayman, Inc. (WuXi XDC) is expected to manufacture ARR-002 drug product and substances for initial clinical studies.
• Clinical Research Organizations (CROs): Fortrea, Inc., Icon Clinical Research Limited, and Syneos Health, LLC.
• Diagnostics Company: Collaborating with a diagnostics company to develop an FDA-approved Next Generation Sequencing (NGS) test for confirming EGFR exon 20 insertion mutations.

Facility Network:

• Manufacturing: Primarily relies on third-party CMOs located in China, although WuXi STA has global manufacturing capabilities.
• Research & Development: Conducted internally and through collaborations.
• Office Space: Leases office space in the San Francisco Peninsula (7,906 sq ft, lease expires August 2027) and Gaithersburg, MD (lease expires February 2027).

Operational Metrics: Not explicitly disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels: ARRIVENT BIOPHARMA, INC. currently has limited commercialization capabilities and no experience commercializing products. If product candidates receive regulatory approval, the company plans to build an internal commercial organization or collaborate with third parties that have established commercialization systems.

Customer Portfolio: Not applicable as no products are commercialized by ARRIVENT BIOPHARMA, INC.

Geographic Revenue Distribution: Not applicable as no revenue has been generated. The company's growth strategy includes developing and commercializing product candidates in foreign markets, particularly outside greater China.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is characterized by rapid technological advancements, intense competition, and a strong emphasis on proprietary and novel products. Lung cancer is a leading cause of cancer-related deaths globally, with NSCLC accounting for approximately 85% of cases. EGFR mutations are common in NSCLC, with uncommon mutations (exon 20 insertion and PACC mutations) representing a significant underserved patient population. The historical failure rate for product candidates in the industry is high.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors (targeting EGFRm-positive NSCLC):

• AstraZeneca plc: Markets osimertinib (TAGRISSO®), a third-generation EGFR TKI and standard of care for classical EGFRm NSCLC, but with limited activity against uncommon mutations.
• Johnson & Johnson: Markets amivantamab, a bispecific antibody approved in combination with chemotherapy for first-line EGFRm NSCLC patients with exon 20 insertion mutations (March 2024 US, July 2024 EU). Amivantamab is intravenously administered and appears to lack brain penetrance.
• Dizal Pharmaceutical: Received FDA approval for sunvozertinib in July 2025 for second or later line NSCLC patients with EGFR exon 20 insertion mutations.
• Taiho Pharmaceutical Co., Ltd. and Cullinan Therapeutics, Inc.: Announced positive Phase 2b clinical trial results in January 2025 for zipalertinib, an oral EGFR inhibitor, in second or later line NSCLC patients with EGFR exon 20 insertion mutations.
• Other Competitors: Blossom Hill Therapeutics, Oric Pharmaceuticals, Black Diamond Therapeutics, Inc., Boehringer Ingelheim, and Bayer AG.
• Withdrawn Products: Mobocertinib (Takeda) received accelerated FDA approval in 2021 for exon 20 insertion mutations but was subsequently withdrawn from the market globally in July 2023 due to futility in a first-line Phase 3 trial.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in oncology, as well as the consolidation of resources among larger competitors through mergers and acquisitions.

Competitive Response Strategy: ARRIVENT BIOPHARMA, INC. aims to maintain its competitive advantage by focusing on the differentiated profile of firmonertinib for uncommon EGFRm NSCLC, executing a robust global clinical development plan, and advancing next-generation ADCs through innovative platforms and strategic business development.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The precise incidence and prevalence of the various NSCLC mutations and gastrointestinal cancers targeted by ARRIVENT BIOPHARMA, INC.'s product candidates are unknown, and market size estimates may prove incorrect. The total addressable market depends on factors such as final product labeling, availability of alternative treatments, safety, efficacy, cost-effectiveness, market acceptance, pricing, and reimbursement. Technology Disruption: The biopharmaceutical industry is subject to rapid technological advancements and intense competition, with the risk that competitors may develop superior, safer, more effective, or less expensive products.

Operational & Execution Risks

Supply Chain Vulnerabilities: ARRIVENT BIOPHARMA, INC. heavily relies on Chinese third-party manufacturers (Raybow, WuXi STA, WuXi XDC) for the supply of drug substance and product for clinical development and future commercialization. The absence of long-term supply agreements and the geographic concentration of manufacturing in China expose the company to risks from production disruptions, changes in U.S. or Chinese government policies, trade wars, political unrest, and public health crises. BIOSECURE Act: The National Defense Authorization Act for Fiscal Year 2026 includes the "Prohibition on Contracting with Certain Biotechnology Providers" (BIOSECURE Act), which may limit ARRIVENT BIOPHARMA, INC.'s ability to obtain federal government grants or sell approved products to the federal government if its Chinese manufacturers are designated as "biotechnology companies of concern." The company is taking measures to strengthen its supply chain and identify alternative manufacturers.

Financial & Regulatory Risks

Market & Financial Risks: Operating results are subject to significant fluctuations due to the timing and costs of R&D, clinical trial outcomes, regulatory approvals, market acceptance, pricing, reimbursement, and general economic conditions. The company has incurred significant operating losses and an accumulated deficit, requiring substantial additional capital. Global economic conditions, credit market volatility, and inflation could adversely affect its ability to raise funds and increase operating costs. Regulatory & Compliance Risks: The company's product candidates are subject to extensive, lengthy, and unpredictable regulatory approval processes by the FDA and comparable foreign authorities. Failure to comply with regulations (e.g., GCP, cGMP, post-marketing requirements) can lead to sanctions, delays, or withdrawal of approvals. While firmonertinib has BTD and Fast Track designation, these do not guarantee faster approval or increased likelihood of success. The potential use of the accelerated approval pathway for certain indications carries the risk of withdrawal if confirmatory trials do not verify clinical benefit. The requirement for companion diagnostics (e.g., for EGFR exon 20 insertion mutations) introduces additional regulatory hurdles. Data Privacy: ARRIVENT BIOPHARMA, INC. is subject to complex and evolving data privacy and protection laws in the U.S. (HIPAA, CCPA, CPRA, state-specific health data laws), EU (GDPR, UK GDPR), and China (Cybersecurity Law, Data Security Law, PIPL). Non-compliance or cybersecurity incidents could lead to regulatory investigations, litigation, fines, reputational harm, and business disruptions. The U.S. Department of Justice's Bulk Transfer Rule (effective October 2025) restricting transfers of bulk sensitive personal data to "countries of concern" (e.g., China) could impact clinical development programs involving data transfers to China. Export Controls: Compliance with U.S. and foreign export/import controls, sanctions, embargoes, and anti-corruption laws (e.g., FCPA) is critical. Geopolitical events and related sanctions could impact clinical trial activities and supply chains.

Geopolitical & External Risks

Geopolitical Exposure: Reliance on Chinese manufacturers exposes the company to risks from U.S. and Chinese government policies, trade disputes, political instability, and economic conditions. Changes in U.S. trade policy, including tariffs, could increase costs and impact global trade. Public Health Threats: Future epidemics or pandemics could disrupt operations, supply chains, clinical trials, and regulatory activities, leading to delays and increased costs.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• EGFR Mutant-Selective TKIs: Focused on firmonertinib, a novel third-generation TKI designed for broad inhibition of classical and uncommon EGFR mutations, including exon 20 insertion and PACC mutations.
• Next-Generation Antibody Drug Conjugates (ADCs): Developing ADCs through collaborations, leveraging:
  • Aarvik Therapeutics, Inc.'s proprietary multi-target, multivalent, site-specific conjugation antibody platform (e.g., ARR-002).
  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd.'s proprietary linker-payload platform and glycan-conjugation technology (e.g., ARR-421 program).
  • CD-H17-targeting ADC (ARR-217) for gastrointestinal cancers. Innovation Pipeline: Includes firmonertinib in pivotal Phase 3 trials and a planned adjuvant study, ARR-217 in Phase 1 clinical development, and ARR-002 in IND-enabling activities.

Intellectual Property Portfolio:

• Patent Strategy: Seeks to obtain and maintain patent protection for compositions of matter, methods of use, formulation, dosing regimens, and manufacturing processes, complemented by trade secret protection.
• Patent Holdings (Firmonertinib, licensed from Allist): Includes issued U.S. reissue patents (2035, 2037 expiry) and international patents for the molecule, mesylate salts, and crystalline forms. Pending applications for methods of manufacturing (2042 expiry) and methods of use for exon 20 insertion, HER2 exon 20 insertion/EGFR rare mutation, and EGFR PACC mutations (2042-2043 expiry).
• Patent Holdings (ARR-217, licensed from Lepu Biopharma): Two PCT applications relating to antibodies and ADCs (2044, 2045 expiry).
• Patent Holdings (ARR-002, licensed from Aarvik): One PCT application relating to antibody scaffolds and ADCs (2044, 2045 expiry).
• Patent Holdings (ARR-421, jointly owned/licensed from Alphamab): A provisional application (jointly owned) and a PCT application relating to camptothecin derivatives and conjugates (2045, 2047 expiry).

Technology Partnerships:

• Shanghai Allist Pharmaceuticals, Co. Ltd: Exclusive license for firmonertinib (ex-Greater China) and joint clinical collaboration.
• Aarvik Therapeutics, Inc.: Research collaboration for next-generation ADCs.
• Jiangsu Alphamab Biopharmaceuticals Co., Ltd.: Research and collaboration agreement for novel ADCs (ex-Greater China).
• Lepu Biopharma Co. Ltd.: Exclusive license for ARR-217 (ex-Greater China).
• InnoCare: Clinical Collaboration Agreement for a clinical trial evaluating firmonertinib in combination with InnoCare’s ICP-189 (SHP2i).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Not explicitly detailed.

Board Composition: The board of directors, led by the audit committee, is actively involved in oversight of Enterprise Risk Management (ERM) activities, including cybersecurity risk management and strategy.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 77 full-time employees.
• Skill Mix: 45 employees are engaged in research and development activities, and 33 employees hold Ph.D. or M.D. degrees.

Talent Management: Acquisition & Retention: The company's objectives include identifying, recruiting, retaining, incentivizing, and integrating employees, advisors, and consultants. Equity and cash incentive plans are used to attract, retain, and reward personnel.

Diversity & Development: Not explicitly detailed.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed.

Supply Chain Sustainability: Not explicitly detailed.

Social Impact Initiatives: Not explicitly detailed.

Business Cyclicality & Seasonality

Demand Patterns: Not explicitly detailed. The business could be adversely affected by unstable economic and political conditions, economic downturns, and geopolitical events, which may decrease demand for product candidates.

Planning & Forecasting: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: ARRIVENT BIOPHARMA, INC. is subject to extensive regulation by the FDA in the United States (under the Federal Food, Drug, and Cosmetic Act and Public Health Service Act) and comparable foreign regulatory authorities (e.g., European Medicines Agency, Medicines and Healthcare Products Regulatory Agency in the UK). This regulation covers all stages of product development, approval, manufacturing, marketing, and post-approval surveillance. The company is also subject to various federal and state healthcare fraud and abuse laws, including the Anti-Kickback Statute, False Claims Act, HIPAA, and Physician Payments Sunshine Act, as well as analogous foreign laws. Trade & Export Controls: The company is subject to U.S. and foreign export and import controls, sanctions, and anti-corruption laws (e.g., FCPA). The U.S. Department of Justice's Bulk Transfer Rule, effective October 2025, restricts transfers of bulk sensitive personal data to "countries of concern" (e.g., China), which could impact clinical development programs involving data transfers to China. Legal Proceedings: ARRIVENT BIOPHARMA, INC. is not currently a party to or aware of any legal proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Tax Strategy & Considerations

Tax Profile: ARRIVENT BIOPHARMA, INC. has incurred losses since inception and has not recognized any current or deferred income tax expense for the year ended December 31, 2025. A full valuation allowance has been recorded against deferred tax assets due to the uncertainty of their realization. The effective tax rate is 0%. Tax Reform Impact: The Inflation Reduction Act of 2022 introduced a 15% corporate minimum tax and a 1% excise tax on certain stock redemptions. The Trump Administration has announced initiatives such as the TrumpRx website for reduced drug prices and potential tariffs on pharmaceutical imports to encourage U.S. manufacturing. Recent PBM regulatory reforms signed into law in February 2026 may also impact the pharmaceutical supply chain.

Insurance & Risk Transfer

Risk Management Framework: ARRIVENT BIOPHARMA, INC. maintains approximately $10.0 million in product liability insurance coverage, along with property, general liability, employment benefits liability, workers’ compensation, malicious invasion of electronic systems, directors’ and officers’, and employment practices insurance.